Prevention of hepatitis A through active or passive immunization; recommendations of the Advisory Committee on Immunization Practices (ACIP)

Bell, Beth P.; Margolis, Harold S.; Shapiro, Craig N.

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Prevention of hepatitis A through active or passive immunization; recommendations of the Advisory Committee on Immunization Practices (ACIP)

Published Date:

December 27, 1996

Status:

superseded

| This document has been replaced by: Prevention of hepatitis A through active or passive immunization; recommendations of the Advisory Committee on Immunization Practices (ACIP)

Source:

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 1996; 45(RR-15):1-30.

[PDF - 394.11 KB]

Details:

Personal Authors:

Bell, Beth P. ; Margolis, Harold S. ; Shapiro, Craig N. ;

Corporate Authors:

United States, Advisory Committee on Immunization Practices ; Centers for Disease Control and Prevention (U.S.) ; National Center for Infectious Diseases (U.S.), Division of Viral and Rckettsial Diseases.

Keywords:

[+]

Pubmed ID:

9005304

Series:

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 45, no. RR-15

Document Type:

Journal Issue

Collection(s):

Stephen B. Thacker CDC Library collection

Description:

This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.

Supporting Files:

No Additional Files

You May Also Like: